z-logo
Premium
Frontline treatment of diffuse large B‐cell lymphoma: Beyond R‐CHOP
Author(s) -
Mondello Patrizia,
Mian Michael
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2613
Subject(s) - diffuse large b cell lymphoma , lymphoma , medicine , chop , germinal center , oncology , standard of care , cell of origin , rituximab , b cell , immunology , cancer , antibody
Although the majority of patients with diffuse large B‐cell lymphoma (DLBCL) can be cured with the standard immunochemotherapy R‐CHOP, one‐third of them relapses with a dismal outcome in most cases. In the recent years, remarkable advances have been achieved based on the discovery of molecular genetics in DLBCL. In addition to the major cell‐of‐origin designations of germinal center B‐cell and activated B‐cell subtypes, next‐generation sequencing has unveiled the remarkable complexity of DLBCL and identified potential molecular targets for tailored therapies. Despite these findings, the current standard of care for DLBCL patients is still R‐CHOP, and optimization of frontline therapy remains an important goal. In this review, we summarize recent updates on the evolution of frontline therapies for DLBCL.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here